Video

Dr Elena Garraldas discusses EP0031 Phase 1 study data

Dr Elena Garralda Cabanas shares her thoughts on the EP0031 phase 1 study data for patients with advanced RET-altered tumors. In this video, Dr. Elena Garralda Cabanas, Co-director of the Clinical Research Program at VHIO, discusses her enthusiasm for the data presented in a phase 1 study for patients with advanced RET-altered tumors. View all [...]

Dr Ander Urruticoechea shares insights on EP0062

Dr Ander shares his insights on EP0062 and the importance of finding effective treatments in oncology In this video, Ander Urruticoechea, MD, Managing Director of the Onkologikoa Foundation, shares insights on EP0062. Dr. Urruticoechea highlights the encouraging responses observed in heavily pre-treated patients, emphasising the importance of finding effective treatments in oncology. View related content

Dr Matthew Krebs on the potential of EP0031

Dr Matthew Krebs on the potential of EP0031 in transforming the landscape of RET-altered cancer In this video, Dr. Matthew Krebs, Clinical Senior Lecturer in Experimental Cancer Medicine at the University of Manchester, shares his thoughts on the potential of EP0031 in transforming the landscape of RET-altered cancer treatment. With preliminary data showcasing encouraging efficacy [...]

Our unique approach to developing cancer medicines faster

Ellipses Pharma on our unique approach to developing cancer medicines faster Hear from our Chairman, Professor Sir Chris Evans, our CEO, Dr Rajan Jethwa and our Global Head of Drug Development, Professor Tobi Arkenau alongside other industry experts and get a look inside Ellipses to discover how our unique approach develops cancer medicines faster. This [...]

Dr Vivek Subbiah talks about the Phase 1/2 trial of EP0031

Phase I/II trial of EP0031, a next generation selective RET inhibitor RET fusions occur in various cancers, and resistance to selpercatinib and pralsetinib, current first generation selective RET inhibitors that are indicated for non-small cell lung cancer and pancreatic cancer, are a growing issue. Vivek Subbiah, MD, The University of Texas MD Anderson Cancer Center, [...]

Dr David Taussig, MRCP, FRCPath, PhD speaks about EP0042

Preliminary results from a first-in-human study of EP0042 in patients with R/R AML David Taussig, MRCP, FRCPath, PhD, The Royal Marsden NHS Foundation Trust, London, UK, discusses preliminary results from an ongoing Phase I/IIa study which is evaluating the safety and tolerability of EP0042, a dual FLT3 and aurora kinase inhibitor, in patients with relapsed/refractory [...]